Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advantage Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$2,176,544

294 payments

Through program year 2025, Advantage Clinical Trials is reported as receiving $2,176,544 in research payments, across 294 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $273,298 15
2024 Research $248,244 25
2023 Research $405,763 30
2022 Research $186,622 34
2021 Research $554,175 58
2020 Research $402,256 90
2019 Research $106,187 42

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $623,726 73 payments
  2. Valneva Austria GmbH $448,284 5 payments
  3. Incyte Corporation $291,890 22 payments
  4. Allergan Inc. $192,887 61 payments
  5. Merck Sharp & Dohme Corporation $174,266 77 payments
  6. Ironwood Pharmaceuticals, Inc $151,675 8 payments
  7. AstraZeneca Pharmaceuticals LP $103,353 8 payments
  8. Ardelyx, Inc. $55,298 3 payments
  9. Sanofi Pasteur Inc. $43,828 7 payments
  10. Perrigo Company plc $32,000 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Randomized Placebocontrolled Observerblinded Trial to Evaluate the Safety of A 6Valent Ospabased Lyme Disease Vaccine Vla15 in Healthy Children 5 Through 17 Years of Age $522,952 38 payments
  2. Safety and Immunogenicity Study of Vla15, A Multivalent Recombinant Ospa Based Vaccine Candidate Against Lyme Borreliosis: A Randomized, Controlled, Observer-Blind Phase 2 Study in A Healthy Pediatric and Adult Study Population. $270,557 2 payments
  3. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa $228,620 14 payments
  4. Safety and Immunogenicity Study of Vla15, A Multivalent Recombinant Ospa Based Vaccine Candidate Against Lyme Borreliosis: A Randomized, Controlled, Observer-Blind Phase 2 Study in A Healthy Pediatric and Adult Study $177,727 3 payments
  5. A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED $159,275 15 payments
  6. C3718-302 $151,675 8 payments
  7. A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $100,774 35 payments
  8. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $89,497 4 payments
  9. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa $63,271 8 payments
  10. Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) $59,086 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record